Cargando…
The Xpert(®) MTB/RIF diagnostic test for pulmonary and extrapulmonary tuberculosis in immunocompetent and immunocompromised patients: Benefits and experiences over 2 years in different clinical contexts
Xpert(®) MTB/RIF has been widely used for tuberculosis (TB) diagnosis in Brazil, since 2014. This prospective observational study aimed to evaluate the performance of Xpert in different contexts during a two-year period: (i) laboratory and clinical/epidemiological diagnosis; (ii) HIV-positive and -n...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7928506/ https://www.ncbi.nlm.nih.gov/pubmed/33657113 http://dx.doi.org/10.1371/journal.pone.0247185 |
_version_ | 1783659871403507712 |
---|---|
author | Tomaz, Ana Paula de Oliveira Raboni, Sonia Mara Kussen, Gislene Maria Botão da Silva Nogueira, Keite Lopes Ribeiro, Clea Elisa Costa, Libera Maria Dalla |
author_facet | Tomaz, Ana Paula de Oliveira Raboni, Sonia Mara Kussen, Gislene Maria Botão da Silva Nogueira, Keite Lopes Ribeiro, Clea Elisa Costa, Libera Maria Dalla |
author_sort | Tomaz, Ana Paula de Oliveira |
collection | PubMed |
description | Xpert(®) MTB/RIF has been widely used for tuberculosis (TB) diagnosis in Brazil, since 2014. This prospective observational study aimed to evaluate the performance of Xpert in different contexts during a two-year period: (i) laboratory and clinical/epidemiological diagnosis; (ii) HIV-positive and -negative populations; (iii) type of specimens: pulmonary and extrapulmonary. Overall, 924 specimens from 743 patients were evaluated. The performance of the assays was evaluated considering culture (Lowenstein Jensen or LJ medium) results and composite reference standard (CRS) classification as gold standard. According to CRS evaluation, 219 cases (29.5%) were classified as positive cases, 157 (21.1%) as ‘possible TB’, and 367 (49.3%) as ‘not TB’. Based on culture, Xpert and AFB smear achieved a sensitivity of 96% and 62%, respectively, while based on CRS, the sensitivities of Xpert, AFB smear, and culture were 40.7%, 20%, and 25%, respectively. The pooled sensitivity and specificity of Xpert were 96% and 94%, respectively. Metric evaluations were similar between pulmonary and extrapulmonary samples against culture, whereas compared to CRS, the sensitivities were 44.6% and 29.3% for the pulmonary and extrapulmonary cases, respectively. The Xpert detected 42/69 (60.9%) patients with confirmed TB and negative culture on LJ medium, and 52/69 (75.4%) patients with negative AFB smear results. There was no significant difference in the diagnostic accuracy based on the types of specimens and population (positive- and negative-HIV). Molecular testing detected 13 cases of TB in culture-negative patients with severe immunosuppression. Resistance to rifampicin was detected in seven samples. Herein, Xpert showed improved detection of pulmonary and extrapulmonary TB cases, both among HIV-positive and -negative patients, even in cases with advanced immunosuppression, thereby performing better than multiple other diagnostic parameters. |
format | Online Article Text |
id | pubmed-7928506 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Public Library of Science |
record_format | MEDLINE/PubMed |
spelling | pubmed-79285062021-03-10 The Xpert(®) MTB/RIF diagnostic test for pulmonary and extrapulmonary tuberculosis in immunocompetent and immunocompromised patients: Benefits and experiences over 2 years in different clinical contexts Tomaz, Ana Paula de Oliveira Raboni, Sonia Mara Kussen, Gislene Maria Botão da Silva Nogueira, Keite Lopes Ribeiro, Clea Elisa Costa, Libera Maria Dalla PLoS One Research Article Xpert(®) MTB/RIF has been widely used for tuberculosis (TB) diagnosis in Brazil, since 2014. This prospective observational study aimed to evaluate the performance of Xpert in different contexts during a two-year period: (i) laboratory and clinical/epidemiological diagnosis; (ii) HIV-positive and -negative populations; (iii) type of specimens: pulmonary and extrapulmonary. Overall, 924 specimens from 743 patients were evaluated. The performance of the assays was evaluated considering culture (Lowenstein Jensen or LJ medium) results and composite reference standard (CRS) classification as gold standard. According to CRS evaluation, 219 cases (29.5%) were classified as positive cases, 157 (21.1%) as ‘possible TB’, and 367 (49.3%) as ‘not TB’. Based on culture, Xpert and AFB smear achieved a sensitivity of 96% and 62%, respectively, while based on CRS, the sensitivities of Xpert, AFB smear, and culture were 40.7%, 20%, and 25%, respectively. The pooled sensitivity and specificity of Xpert were 96% and 94%, respectively. Metric evaluations were similar between pulmonary and extrapulmonary samples against culture, whereas compared to CRS, the sensitivities were 44.6% and 29.3% for the pulmonary and extrapulmonary cases, respectively. The Xpert detected 42/69 (60.9%) patients with confirmed TB and negative culture on LJ medium, and 52/69 (75.4%) patients with negative AFB smear results. There was no significant difference in the diagnostic accuracy based on the types of specimens and population (positive- and negative-HIV). Molecular testing detected 13 cases of TB in culture-negative patients with severe immunosuppression. Resistance to rifampicin was detected in seven samples. Herein, Xpert showed improved detection of pulmonary and extrapulmonary TB cases, both among HIV-positive and -negative patients, even in cases with advanced immunosuppression, thereby performing better than multiple other diagnostic parameters. Public Library of Science 2021-03-03 /pmc/articles/PMC7928506/ /pubmed/33657113 http://dx.doi.org/10.1371/journal.pone.0247185 Text en © 2021 Tomaz et al http://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/) , which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. |
spellingShingle | Research Article Tomaz, Ana Paula de Oliveira Raboni, Sonia Mara Kussen, Gislene Maria Botão da Silva Nogueira, Keite Lopes Ribeiro, Clea Elisa Costa, Libera Maria Dalla The Xpert(®) MTB/RIF diagnostic test for pulmonary and extrapulmonary tuberculosis in immunocompetent and immunocompromised patients: Benefits and experiences over 2 years in different clinical contexts |
title | The Xpert(®) MTB/RIF diagnostic test for pulmonary and extrapulmonary tuberculosis in immunocompetent and immunocompromised patients: Benefits and experiences over 2 years in different clinical contexts |
title_full | The Xpert(®) MTB/RIF diagnostic test for pulmonary and extrapulmonary tuberculosis in immunocompetent and immunocompromised patients: Benefits and experiences over 2 years in different clinical contexts |
title_fullStr | The Xpert(®) MTB/RIF diagnostic test for pulmonary and extrapulmonary tuberculosis in immunocompetent and immunocompromised patients: Benefits and experiences over 2 years in different clinical contexts |
title_full_unstemmed | The Xpert(®) MTB/RIF diagnostic test for pulmonary and extrapulmonary tuberculosis in immunocompetent and immunocompromised patients: Benefits and experiences over 2 years in different clinical contexts |
title_short | The Xpert(®) MTB/RIF diagnostic test for pulmonary and extrapulmonary tuberculosis in immunocompetent and immunocompromised patients: Benefits and experiences over 2 years in different clinical contexts |
title_sort | xpert(®) mtb/rif diagnostic test for pulmonary and extrapulmonary tuberculosis in immunocompetent and immunocompromised patients: benefits and experiences over 2 years in different clinical contexts |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7928506/ https://www.ncbi.nlm.nih.gov/pubmed/33657113 http://dx.doi.org/10.1371/journal.pone.0247185 |
work_keys_str_mv | AT tomazanapauladeoliveira thexpertmtbrifdiagnostictestforpulmonaryandextrapulmonarytuberculosisinimmunocompetentandimmunocompromisedpatientsbenefitsandexperiencesover2yearsindifferentclinicalcontexts AT rabonisoniamara thexpertmtbrifdiagnostictestforpulmonaryandextrapulmonarytuberculosisinimmunocompetentandimmunocompromisedpatientsbenefitsandexperiencesover2yearsindifferentclinicalcontexts AT kussengislenemariabotao thexpertmtbrifdiagnostictestforpulmonaryandextrapulmonarytuberculosisinimmunocompetentandimmunocompromisedpatientsbenefitsandexperiencesover2yearsindifferentclinicalcontexts AT dasilvanogueirakeite thexpertmtbrifdiagnostictestforpulmonaryandextrapulmonarytuberculosisinimmunocompetentandimmunocompromisedpatientsbenefitsandexperiencesover2yearsindifferentclinicalcontexts AT lopesribeirocleaelisa thexpertmtbrifdiagnostictestforpulmonaryandextrapulmonarytuberculosisinimmunocompetentandimmunocompromisedpatientsbenefitsandexperiencesover2yearsindifferentclinicalcontexts AT costaliberamariadalla thexpertmtbrifdiagnostictestforpulmonaryandextrapulmonarytuberculosisinimmunocompetentandimmunocompromisedpatientsbenefitsandexperiencesover2yearsindifferentclinicalcontexts AT tomazanapauladeoliveira xpertmtbrifdiagnostictestforpulmonaryandextrapulmonarytuberculosisinimmunocompetentandimmunocompromisedpatientsbenefitsandexperiencesover2yearsindifferentclinicalcontexts AT rabonisoniamara xpertmtbrifdiagnostictestforpulmonaryandextrapulmonarytuberculosisinimmunocompetentandimmunocompromisedpatientsbenefitsandexperiencesover2yearsindifferentclinicalcontexts AT kussengislenemariabotao xpertmtbrifdiagnostictestforpulmonaryandextrapulmonarytuberculosisinimmunocompetentandimmunocompromisedpatientsbenefitsandexperiencesover2yearsindifferentclinicalcontexts AT dasilvanogueirakeite xpertmtbrifdiagnostictestforpulmonaryandextrapulmonarytuberculosisinimmunocompetentandimmunocompromisedpatientsbenefitsandexperiencesover2yearsindifferentclinicalcontexts AT lopesribeirocleaelisa xpertmtbrifdiagnostictestforpulmonaryandextrapulmonarytuberculosisinimmunocompetentandimmunocompromisedpatientsbenefitsandexperiencesover2yearsindifferentclinicalcontexts AT costaliberamariadalla xpertmtbrifdiagnostictestforpulmonaryandextrapulmonarytuberculosisinimmunocompetentandimmunocompromisedpatientsbenefitsandexperiencesover2yearsindifferentclinicalcontexts |